Houston, TX - May 20, 2010 – Capital Royalty L.P. (“Capital Royalty”) announced today that Mike Weinmann has been promoted to Managing Director. Mr. Weinmann leads Capital Royalty’s New York office, where his responsibilities include identifying, structuring, and leading due diligence on royalty monetization transactions. Mr. Weinmann is also a member of the firm’s Investment Committee.
“Mike has been an invaluable asset to Capital Royalty since joining the Firm as a Principal in March of 2009. Mr. Weinmann’s commanding knowledge of the royalty space, intimate involvement in the creation of the royalty bond product, and extensive industry relationships have been integral to Capital Royalty’s success and investment performance over the past year. This promotion reflects his past achievements as well as our expectations for his continued leadership as a senior member of the management team,” said Charles W. Tate, Founding Partner and Chairman.
“I am extremely gratified by the world-class investment team that Capital Royalty has assembled over the past year – a team that today represents the industry’s foremost pioneers and innovators in healthcare financing, including Mr. Weinmann. Collectively, Capital Royalty’s investment team represents more than 140 years of healthcare, capital markets, private equity and investment banking experience, having managed over $4.2 billion in healthcare assets and completed more than 50 royalty transactions representing $3.7 million in capital over the past fifteen years. The experience our investment team positions Capital Royalty to drive our industry’s innovation and market leadership into the future,” Mr. Tate said.
Prior to joining Capital Royalty, Mr. Weinmann most recently served as an Executive Director in Morgan Stanley's Global Capital Markets Division, specializing in structured debt financings and intellectual property monetizations. Mr. Weinmann was a co-developer of biopharmaceutical royalty bonds and marketed the first 14 royalty bond transactions raising more than $1.8 billion in capital. Over the course of his career, Mr. Weinmann has been responsible for $3.4 billion of healthcare royalty monetizations. He joined Morgan Stanley in 1999 and had a leading role in the structuring of debt financings involving pharmaceutical royalties, infrastructure assets, aircraft, rolling stock, ships, power generation facilities, and real estate.
ABOUT CAPITAL ROYALTY L.P.
Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bond and other royalty monetization structures. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors. The Firm is headquartered in Houston, Texas with offices in New York, New York and Boulder, Colorado. For further information, please visit www.capitalroyalty.com.